The Rationale and Evidence for SGLT2 Inhibitors as a Treatment for Nondiabetic Glomerular Disease

BACKGROUND: Recent studies show that sodium-glucose cotransporter 2 inhibitors (SGLT2i), originally approved for glycemic control in patients with type 2 diabetes, also exert renoprotective effects independently from effects on dysglycemia. Moreover, recent work indicates that SGLT2i treatment may b...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyata, Kana N., Zhang, Shao-Ling, Chan, John S.D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677741/
https://www.ncbi.nlm.nih.gov/pubmed/36751486
http://dx.doi.org/10.1159/000513659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677741/
https://www.ncbi.nlm.nih.gov/pubmed/36751486
http://dx.doi.org/10.1159/000513659

Ejemplares similares